Here are the 8-K filings from Obsidian Therapeutics, Inc. (OBX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow OBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OBX filings page.
Obsidian Therapeutics, Inc. filed an amendment to provide full historical and pro forma financials reflecting its merger with Galera Therapeutics and related financing. The operating company, Obsidian Therapeutics Sub, Inc., is a clinical‑stage cell therapy developer focused on OBX‑115, a TIL product in Phase 2 for advanced melanoma and Phase 1 for NSCLC.
For the six months ended June 30, 2026, Obsidian Sub reported a net loss of $45.5 million on research and development expenses of $37.3 million and general and administrative expenses of $9.1 million. Cash, cash equivalents and marketable securities were $34.4 million as of June 30, 2026, down from $80.5 million at year‑end 2025, reflecting heavy operating cash use.
On July 31, 2026, immediately before the merger closing, a Concurrent PIPE Financing raised gross proceeds of $350.0 million, and the combined company now expects its cash resources to fund operations into the second half of 2028, alleviating prior substantial doubt about going concern. Pro forma, approximately 61.8 million shares of Parent common stock are outstanding, with legacy Obsidian holders owning about 51.5%, PIPE investors 47.2% and legacy Galera holders 1.3%.